Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Acacia Pharma Group plc
  6. Summary
    ACPH   GB00BYWF9Y76

ACACIA PHARMA GROUP PLC

(ACPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
2.265(c) 2.345(c) 2.31(c) 2.275(c) 2.295(c) Last
31 115 94 917 46 108 52 358 32 901 Volume
+2.03% +3.53% -1.49% -1.52% +0.88% Change
More quotes
Estimated financial data (e)
Sales 2021 5,15 M 7,12 M 7,12 M
Net income 2021 -37,0 M -51,2 M -51,2 M
Net cash position 2021 2,69 M 3,71 M 3,71 M
P/E ratio 2021 -5,19x
Yield 2021 -
Sales 2022 30,2 M 41,8 M 41,8 M
Net income 2022 -29,6 M -40,9 M -40,9 M
Net Debt 2022 25,6 M 35,4 M 35,4 M
P/E ratio 2022 -6,59x
Yield 2022 -
Capitalization 195 M 270 M 270 M
EV / Sales 2021 37,4x
EV / Sales 2022 7,31x
Nbr of Employees 72
Free-Float 63,1%
More Financials
Company
Acacia Pharma Group PLC is a United Kingdom-based company specialized in the pharmaceutical industry. The pharmaceutical group focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. Its pipeline includes BAREMIS, an intravenous formulation of amisulpride, which is a selective dopamine antagonist that has completed phase 3 clinical development for the... 
Sector
Pharmaceuticals
Calendar
09/03Earnings Release
More about the company
Ratings of Acacia Pharma Group plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ACACIA PHARMA GROUP PLC
07/09PRESS RELEASE : ???????paion announces that nmpa accepts submission of new drug ..
DJ
07/05CORRECTION : Transparency Notification - PDF of Notification attached
AQ
07/01ACACIA PHARMA : Transparency Notification
AQ
07/01ACACIA PHARMA : Announces Significant Continued Progress with Formulary Uptake o..
PU
07/01ACACIA PHARMA : Significant Continued Progress with Formulary Uptake of BARHEMSY..
AQ
07/01Acacia Pharma Group plc Announces Its Significant Continued Progress Withform..
CI
06/29PRESS RELEASE : Paion receives uk mhra approval of byfavo (remimazolam) for proc..
DJ
06/29ACACIA PHARMA : Results of Annual General Meeting
AQ
06/01ACACIA PHARMA : Corporate Presentation – Jefferies Healthcare Conference, ..
PU
05/25ACACIA PHARMA GROUP PLC : Notice of Annual General Meeting
AQ
05/25ACACIA PHARMA : to Participate in Jefferies Virtual Healthcare Conference
AQ
05/19ACACIA PHARMA : Appoints Lilly Official as New Chief Commercial Officer
MT
05/19ACACIA PHARMA : Appoints Debra Hussain as Chief Commercial Officer
AQ
05/19Acacia Pharma Group plc Appoints Debra Hussain as Chief Commercial Officer
CI
05/12PRESS RELEASE : ???????paion ag publishes group quarterly statement for the firs..
DJ
More news
News in other languages on ACACIA PHARMA GROUP PLC
07/09DGAP-NEWS : ???????paion gibt annahme des remimazolam-besilat-zulassungsantrags ..
07/05BRUSSELS STOCK EXCHANGE : Bel20 sluit hoger af
07/05Coltrane kleiner in Acacia Pharma
07/05Bel20 herstelt in middaghandel
07/05Lichtrode beurs na positieve opening
More news
Chart ACACIA PHARMA GROUP PLC
Duration : Period :
Acacia Pharma Group plc Technical Analysis Chart | ACPH | GB00BYWF9Y76 | MarketScreener
Technical analysis trends ACACIA PHARMA GROUP PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 195,98 GBX
Average target price 686,80 GBX
Spread / Average Target 250%
EPS Revisions
Managers and Directors
Michael Bolinder Chief Executive Officer & Executive Director
Gary G. Gemignani Chief Financial Officer
Scott A. Byrd Chairman
Gabriel Fox Chief Medical Officer
John Robert Brown Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ACACIA PHARMA GROUP PLC-13.23%241
JOHNSON & JOHNSON9.21%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.58%218 198
ELI LILLY AND COMPANY44.05%209 276
NOVARTIS AG1.10%207 246